

About Us

We are a team of researchers at Oregon Health and Science University and 20+ partner sites across the United States and Canada conducting a Patient-Centered Research Outcomes Institute (PCORI)-funded pragmatic trial to determine whether 2-drug therapy is as effective as and more tolerable than 3-drug therapy for pulmonary MAC disease, or "MAC2v3".

Clinicaltrials.gov Information Page with eligibility criteria: https://clinicaltrials.gov/ct2/show/NCT03672630

Do you have patients who are newly diagnosed with pulmonary MAC and ready to start treatment?

Let us support you as you treat your uncomplicated pulmonary MAC patients with guidance from NTM experts! MAC2v3 study participation has been expanded to include virtual enrollment and telehealth visits, which means the study team is now able to enroll patients from any health care provider nationwide. However, **we need to enroll them prior to starting treatment**. Once randomized, patients are monitored per usual care in collaboration with your clinic. Data collection is managed by the enrolling site. Please contact <u>MAC2v3@ohsu.edu</u> if you are interested in participating and providing this opportunity to your patients.

Physician Benefits



- Access to study standard of care monitoring guidelines developed by NTM experts
- Collaborative care with Study Investigators at NTM Centers
- Contribute to patient-focused research to redefine standard of care for uncomplicated pulmonary MAC disease




- Refer your patient for virtual enrollment while continuing to care for them as their treating physician in collaboration with Study Investigators, or:
- Refer your patient to the nearest study site for treatment and enrollment in the study

In either case, the enrolling study site manages observational data collection.

How to Participate

Find MAC2v3 sites in your region



Have questions or interested in participating?

MAC2v3@ohsu.edu (503) 346-3752